Syneos up for sale — report; Takeda's Ninlaro fails PhIII in multiple myeloma; EMA braces for drug shortage
→ Amid industry-wide consolidation, the CRO Syneos is considering putting itself up for sale, Reuters reports, and has hired …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
